HMG-CoA reductase inhibitors and method

Details HMG-CoA reductase inhibitors and method HMG-CoA reductase inhibitors and method

2003-06-24

2004-11-02

Huang, Evelyn Mei (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S023000, C546S080000, C546S093000, C544S171000, C544S171000, C514S291000, C514S213010

Reexamination Certificate

active

06812345

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to compounds and pharmaceutical compositions useful as hypocholesterolemic and hypolipidemic agents. More particularly, this invention concerns (1) certain inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) that include a pyridine containing nucleus attached by means of a linker to an HMG-binding domain sidechain, (2) pharmaceutical compositions containing such compounds and (3) a method of lowering blood serum cholesterol levels and modulating blood serum lipid levels employing such pharmaceutical compositions.
BACKGROUND OF THE INVENTION
U.S. Pat. No. 5,686,433 to Robl-discloses the structure
wherein:
Am is a binding domain sidechain;
X is a linker;
R
1
and R
2
are the same or different and are each independently selected from
(i) hydrogen,
(ii) alkyl,
(iii) aryl,
(iv) cycloalkyl,
(v) aralkyl,
(vi) aralkoxy,
(vii) alkenyl,
(viii) cycloalkenyl, and
(ix) heterocyclo (e.g., thienyl, benzodioxolyl);
R
3
is selected from
(i) hydrogen,
(ii) lower alkyl,
(iii) aryl,
(iv) cycloalkyl,
(v) alkoxy,
(vi) aralkyl,
(vii) aralkoxy,
(viii) alkenyl,
(ix) cycloalkenyl,
(x) halo-substituted alkyl,
(xi) adamantyl, and
(xii) heterocyclo (e.g., thienyl, benzodioxolyl);
R
4
is selected from
(i) hydrogen,
(ii) lower alkyl,
(iii) aryl,
(iv) cycloalkyl,
(v) alkoxy,
(vi) aralkyl,
(vii) aralkoxy,
(viii) alkenyl,
(ix) cycloalkenyl,
(x) adamantyl,
(xi) halogen,
(xii) halo-substituted alkyl (e.g., trifluoromethyl), and
(xiii) heterocyclo (e.g., thienyl, benzodioxolyl); or R
3
and R
4
taken together can be
but when A
m
is
or a &dgr; lactone thereof, R
3
and R
4
cannot be (CH═CH)
2
;
R
6
is hydrogen or lower alkyl;
R
8
is hydrogen, lower alkyl, alkali metal, or alkaline earth metal;
n is 0 or 1;
p is 3, 4 or 5;
q is 0, 1, 2, or 3; and
r is 0, 1, 2, or 3.
In preferred embodiments (Am) is an HMG-binding domain sidechain having a dihydroxy or a phosphinic acid function.
The phosphinic (or phosphonic when X is CH
2
—O—) acid HMG-binding domain sidechain (A
1
) is
wherein R
5
and R
7
are independently selected from hydrogen, lower alkyl, alkali metal ion and alkaline earth metal ion; and R
6
is hydrogen or lower alkyl.
The dihydroxy acid binding domain sidechain (A
2
is
wherein R
6
is hydrogen or lower alkyl, R
8
is hydrogen or lower alkyl in free acid form or in the form of a physiologically acceptable and hydrolyzable ester or &dgr; lactone thereof (i.e., when Am is
In addition, R
8
can be alkali metal ion or alkaline earth metal ion.
A suitable linker (X) is —(CH
2
)
a
—, —CH═CH—, —C≡C—, —CH
2
O—, wherein O is linked to the phosphorous atom or the aromatic anchor when Am is A
1
, and wherein O is linked to the aromatic anchor when Am is A
2
, and wherein “a” is 1, 2, or 3.
BRIEF DESCRIPTION OF THE INVENTION
In accordance with the present invention, there are provided certain pyridine-containing compounds that are potent inhibitors of cholesterol biosynthesis by virtue of their ability to inhibit the enzyme 3-methyl-glutaryl-coenzyme A reductase (HMG-CoA reductase).
In particular, in its broadest chemical compound aspect, the present invention provides compounds of the formula
wherein X is O, S, SO, SO
2
or NR
7
;
is 0 or 1;
R
1
and R
2
are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl;
R
3
is H, or lower alkyl or a metal ion (such as an alkali metal or an alkaline earth metal);
R
4
is H, halogen, CF
3
, hydroxy, alkyl, alkoxy, carboxyl, carboxylalkyl-, aminoalkyl, amino, alkanoylamino, aroylamino, cyano, alkoxyCON(R
7d
)—, R
7f
R
7g
NCO—, R
7f
R
7g
NCO
2
—, R
7e
SO
2
N(R
7d
)—, R
7f
R
7g
NSO
2
N(R
7d
) —, R
7e
OCO
2
— or R
7e
OCO—;
R
7
is H, alkyl, aryl, alkanoyl, aroyl, alkoxycarbonyl, R
7a
SO
2
—, R
7b
R
7c
NSO
2
— or R
7b
R
7c
NCO—;
R
7a
and R
7e
are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl,
R
7b
and R
7c
, and R
7f
and R
7g
, and R
7d
are the same or different and are independently selected from H, alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl; or R
7b
and R
7c
may be taken together with the nitrogen to which they are attached to form a stable 3 to 8 membered heterocyclic ring, which where applicable, includes a total of 1 to 3 heteroatoms in the ring, which heteroatoms may be N, O or S; or R
7f
and R
7g
may be taken together with the nitrogen to which they are attached to form a stable 3 to 8 membered heterocyclic ring which, where applicable, includes a total of 1 to 3 heteroatoms in the ring, which heteroatoms may be N, O or S;
R
8
is H or lower alkyl;
R
9
and R
10
are the same or different and are independently selected from H or alkyl, or where at least one of R
9
and R
10
is alkyl, R
9
and R
10
may be taken together with the carbon or carbons to which they are attached to form a 3 to 7 membered carbocyclic ring, which may include a spirocyclic ring;
and
represents a single bond or a double bond (which may be cis or trans);
and including pharmaceutically acceptable salts thereof where R
3
is H, esters thereof, prodrug esters thereof, and all stereoisomers thereof.
Preferably, the Z group will be in form of a free acid, a physiologically acceptable and hydrolyzable ester or &dgr; lactone thereof, or an alkali metal salt, alkaline earth metal salt or an amino acid salt.
It is preferred that X is O, SO
2
or NR
7
where R
7
is R
7a
SO
2
—.
Preferred are compounds of formula I of the invention wherein
R
1
and R
2
are independently selected from alkyl, cycloalkyl and aryl;
R
4
is H, alkyl or halogen;
X is O; and
n is o.
More preferred are compounds of formula I of the invention wherein R
1
is aryl (especially substituted aryl as defined hereinafter);
R
2
is alkyl or cycloalkyl;
R
4
is H;
R
9
and R
10
are H;
X is O;
n is o; and
is a double bond.
Still more preferred are compounds of formula I of the invention wherein
R
1
is substituted aryl, preferably 4-fluorophenyl, 4-fluoro-3-methylphenyl or 3,5-dimethylphenyl;
R
2
is alkyl or cycloalkyl, preferably isopropyl, t-butyl or cyclopropyl;
R
4
is H;
X is O;
n is o;
is a double bond, preferably “trans”; and
or an alkali or alkaline earth metal salt thereof or an amino acid salt.
Most preferred compounds of formula I of the invention will have the structure
or an alkali or alkaline earth metal (such as Na, K or Ca) salt thereof, or an amino acid salt (such as arginine), wherein R
5
and R
6
are the same or different and independently selected from H, halogen and/or alkyl (preferably 4-fluoro, 4-fluoro-3-methyl or 3,5-dimethyl); and
R
2
is alkyl or cycloalkyl, preferably isopropyl, t-butyl or cyclopropyl.
In another aspect, the present invention provides pharmaceutical compositions, useful as hypolipidemic or hypocholesterolemic agents, or hypotriglyceridemic agents, or anti-Alzheimer's agents, or anti-osteoporosis agents as well as other uses as described herein, comprising a hypolipidemic or hypocholesterolemic or hypotriglyceridemic or anti-Alzheimer's disease or anti-osteoporosis amount, or other therapeutically effective amount (depending upon use) of a compound of formula I in accordance with this invention, in combination with a pharmaceutically acceptable carrier.
In another aspect, the present invention provides a method of inhibiting cholesterol biosynthesis or lowering blood serum cholesterol levels and/or modulating blood serum cholesterol levels such as lowering LDL cholesterol and/or increasing HDL cholesterol, or treating dyslipidemia, mixed dyslipidemia, hyperlipidemia, hypercholesterolemia, hypo &agr;-lipoproteinemia, LDL Pattern B, LDL Pattern A, hyperlipoproteinemia or hypertriglyceridemia, and other aberrations of apolipoprotein B metabolism, or reducing levels of Lp(a), or treating or preventing other cholesterol-related diseases, or treating or preventing or reversing progression of atherosclerosis, or pr

Affiliated with

Also associated with

Rating

HMG-CoA reductase inhibitors and method does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HMG-CoA reductase inhibitors and method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HMG-CoA reductase inhibitors and method will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3304480